Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN)
Eligible age
30–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Insomnia is a common sleep disorder characterized by difficulty falling asleep, staying asleep, or both, despite appropriate opportunities for getting sleep. Growing evidence has associated insomnia with prevalent and incidence of hypertension. However, the impact of the pharmacologic treatment of insomnia on office blood pressure (BP) and 24-h ambulatory BP monitoring (ABPM) in unclear. Therefore, the aim of this study is to evaluate the impact of eszopiclone, a non-benzodiazepine hypnotic that binds to certain subunits of the gamma-aminobutyric acid type A receptors GABA-A (such as α1, α3, and α5) promoting relaxation and sleep. Eszopiclone is an FDA-approved treatment for insomnia in those who have difficulty falling asleep and for patients with difficulty staying asleep (sleep maintenance).
Sponsor: University of Sao Paulo
You may qualify if…
- ✓ Adults (30 to 75 years-old)
- ✓ BMI \<40Kg/m2;
- ✓ Availability to participate
- ✓ History of HBP under regular treatment (systolic pressure between 130-160 and diastolic pressure between 80-100 mmHg).
You may not qualify if…
- ✕ Use of benzodiazepines or "Z" drugs;
- ✕ Night workers;
- ✕ History of severe chronic obstructive pulmonary disease (COPD);
- ✕ Heart failure (ejection fraction \<40% on echocardiogram);
- ✕ Prior stroke;
- ✕ Generalized anxiety disorder (GAD-7 \>14 points) and severe depression (Beck);
- ✕ Severe liver disease;
- ✕ Alcohol abuse;
Source: ClinicalTrials.gov · NCT07018557 · last updated 2025-06-12